English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Background: Promising results for mammary carcinoma treatment withphotodynamic therapy (PDT) presuppose a careful selection of irradiation lightwavelength. Methods: 4T1 tumors implanted in NOD-SCID mice were treated withMetvix-PDT under 625 nm, 660 nm and their combination light, for a fixedradiant exposure. The therapeutic outcome was assessed through Monte Carlobased computational simulations along with a preliminary in vivo study, wherefluorescence, size and temperature measurements were conducted. Results: Thelight source combination protocol presents great potential, since it results inhigh cytotoxic products levels and reduced treatment times; while the in vivofindings, regarding the harvested tumor mass, also support this hypothesis. Theirradiation with 625 nm beam alone presented better results for most of the invivo measured parameters. The mouse treated with only the 660 nm light sourcehad the highest un-photobleached photosensitizer (PS) signal, the lowest bodytemperature, the heaviest harvested tumor and the lowest estimatedconcentration of PDT cytotoxic products. Conclusions: The use of 625 nmirradiation light matches the PS excitation band but is preferable only fortreatment of superficial tumors. For deeper laying masses, the simultaneous useof longer wavelengths enhances the therapeutic outcome due to their increasedpenetration depth.

Photodynamic therapy of 4T1 tumors in NOD-SCID mice